What you should know:
1. Shai Friedland, MD, of Stanford (Calif.) Health Care, presented interim study results on the test’s effectiveness at the 2020 ASCO Virtual Scientific Program.
2. The study evaluated 354 patients with no prior history of CRC who received the blood-based test before having a colonoscopy.
3. The test detected CRC with 90 percent specificity and 100 percent sensitivity. It detected advanced adenomas with 75.5 percent sensitivity. Overall, the test boasts a 79.7 percent sensitivity rate for advanced adenomas and CRC.
4. The FightSight assay can detect three biomarkers in a patient.
More articles on healthcare:
14 ASCs opened or announced in July
Five COVID-19 updates for ASC leaders
Compass Surgical Partners hires executive administrator
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
